Korro Bio, Inc. KRRO 深 沪
已收盘 03-27 16:00:00 美东时间
10.40
-0.510
-4.67%
华盛通- 最 高10.87
- 今 开10.80
- 成交量 12.71万股
- 最 低 10.25
- 昨 收 10.91
- 总市值 9793.99万
- 52周最高 55.89
- 市盈率 静 --
- 换手率 1.35%
- 52周最低 5.2044
- 委 比 12.36%
- 总股本 941.73万
- 历史最高 2918.50
- 量 比 0.78
- 振 幅 5.68%
- 历史最低 5.2044
- 每 手 1
- 风险率 11.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
Raymond James Upgrades Korro Bio to Outperform, Announces $23 Price Target
Raymond James analyst Steven Seedhouse upgrades Korro Bio (NASDAQ:KRRO) from Market Perform to Outperform and announces $23 price target.
03-13 19:51
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares moved upwards by 70.7% to $0.38 during ...
03-13 05:05
Korro Bio Q4 EPS $(5.32) Misses $(2.05) Estimate, Sales $1.290M Beat $670.000K Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(5.32) per share which missed the analyst consensus estimate of $(2.05) by 159.39 percent. This is a 135.4 percent decrease over losses of $(2.26) per share from the
03-13 04:20
Korro Bio Secures ~$85M PIPE Financing Via Subscription Agreement
Financing led by new investor Venrock Healthcare Capital Partners, with participation from new and existing investors Proceeds support the achievement of value inflection points for multiple RNA editing programs
03-09 19:36
美股大行评级 | 潜在涨幅108.69%！Stephens & Co.维持圣玛丽石油勘测"超配"评级，上调目标价至49美元
今日重点评级关注：Stephens & Co.：维持圣玛丽石油勘测"超配"评级，目标价从48美元升至49美元；花旗：维持IDEAYA Biosciences"买入"评级，目标价从64美元升至65美元
02-20 15:57
This Chewy Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
02-19 19:58
William Blair Upgrades Korro Bio to Outperform
William Blair analyst Myles Minter upgrades Korro Bio (NASDAQ:KRRO) from Market Perform to Outperform.
02-17 23:23
美股大行评级 | Meta 、IBM、拉姆研究、布林克国际等获多家机构上调目标价；微软、特斯拉、ServiceNow、自动数据处理等遭多家下调评级
今日重点评级关注：Piper Sandler：上调Korro Bio评级至"超配"，目标价从11美元升至30美元；Piper Sandler：维持Nurix Therapeutics"超配"评级，目标价从32美元升至35美元
01-30 17:38
This Fortinet Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-29 20:41
